Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna

Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna original article Wien Klin Wochenschr (2017) 129:517–526 DOI 10.1007/s00508-016-1162-y Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna Sebastian Steiner · Theresa Bucsics · Philipp Schwabl · Mattias Mandorfer · Bernhard Scheiner · Maximilian Christopher Aichelburg · Katharina Grabmeier-Pfistershammer · Peter Ferenci · Michael Trauner · Markus Peck-Radosavljevic · Thomas Reiberger Received: 18 August 2016 / Accepted: 19 December 2016 / Published online: 27 January 2017 © The Author(s) 2017. This article is available at SpringerLink with Open Access. Summary of SOF/LDV and 60% of 2D/3D patients prior to Aim We aimed to investigate the efficacy of interferon anti-HCV treatment due to expected DDIs. We ob- and ribavirin-free sofosbuvir/ledipasvir (SOF/LDV) served sustained virologic response (SVR) rates of and ritonavir boosted paritaprevir/ombitasvir with 100% in patients treated with SOF/LDV (19/19) and or without dasabuvir (2D/3D) regimens in a real-life 2D/3D (14/14). One 2D/3D patient was lost to follow- cohort of human immunodeficiency virus/hepatitis up, while two SOF/LDV patients died during ther- C virus (HIV/HCV) coinfected patients. The study apy from non-treatment-related causes. They were focused on efficacy, need for changes in antiretroviral excluded from the analysis. Between baseline and fol- therapy (ART) due to http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Wiener klinische Wochenschrift Springer Journals

Loading next page...
 
/lp/springer_journal/progress-in-eradication-of-hcv-in-hiv-positive-patients-with-3xBc6efYbZ

References (50)

Publisher
Springer Journals
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Medicine/Public Health, general; Internal Medicine; Endocrinology; Gastroenterology; Pneumology/Respiratory System
ISSN
0043-5325
eISSN
1613-7671
DOI
10.1007/s00508-016-1162-y
Publisher site
See Article on Publisher Site

Abstract

original article Wien Klin Wochenschr (2017) 129:517–526 DOI 10.1007/s00508-016-1162-y Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna Sebastian Steiner · Theresa Bucsics · Philipp Schwabl · Mattias Mandorfer · Bernhard Scheiner · Maximilian Christopher Aichelburg · Katharina Grabmeier-Pfistershammer · Peter Ferenci · Michael Trauner · Markus Peck-Radosavljevic · Thomas Reiberger Received: 18 August 2016 / Accepted: 19 December 2016 / Published online: 27 January 2017 © The Author(s) 2017. This article is available at SpringerLink with Open Access. Summary of SOF/LDV and 60% of 2D/3D patients prior to Aim We aimed to investigate the efficacy of interferon anti-HCV treatment due to expected DDIs. We ob- and ribavirin-free sofosbuvir/ledipasvir (SOF/LDV) served sustained virologic response (SVR) rates of and ritonavir boosted paritaprevir/ombitasvir with 100% in patients treated with SOF/LDV (19/19) and or without dasabuvir (2D/3D) regimens in a real-life 2D/3D (14/14). One 2D/3D patient was lost to follow- cohort of human immunodeficiency virus/hepatitis up, while two SOF/LDV patients died during ther- C virus (HIV/HCV) coinfected patients. The study apy from non-treatment-related causes. They were focused on efficacy, need for changes in antiretroviral excluded from the analysis. Between baseline and fol- therapy (ART) due to

Journal

Wiener klinische WochenschriftSpringer Journals

Published: Jan 27, 2017

There are no references for this article.